Sustainability to drive Pregis product development in Europe

Published: 10-Dec-2010
Packaging Finance

To focus on environmentally friendly products in 2011

The new president of Pregis’ European protective packaging business says the firm will focus on sustainable products in new product developments for 2011.

Kevin Baudhuin has been president of Pregis’ North American protective packaging business since 2007.

He has now been promoted to president of global protective packaging where he will lead Pregis Protective Packaging Europe.

Baudhuin said the firm aimed to create a broad environmentally friendly product portfolio suitable for a number of markets, including medical and pharmaceutical products.

The company already offers its Superlite poly Mailer and EP-Flex Renew biodegradable film products.

‘We recognise that any sustainable solution must still meet other key requirements such as high performance and cost-effectiveness and we will therefore ensure that our products continue to satisfy all these criteria,’ said Baudhuin.

He added that the firm’s growth strategy would focus on three main areas of sustainability, innovation and customer partnerships.

See more

You may also like

Manufacturing

Pregis announces film converting, equipment assembly facilities

Read more
The company’s converting equipment has been self-manufactured and was designed to ensure it’s capable of meeting performance goals including output, sealing and puncture resistance

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing sustainable change through labelling choice Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
  2. Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
  3. Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
  4. CARBOGEN AMCIS secures refinancing to support growth and investment CARBOGEN AMCIS today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG
  5. Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer

You may also like

Manufacturing

Pregis announces film converting, equipment assembly facilities

The company’s converting equipment has been self-manufactured and was designed to ensure it’s capable of meeting performance goals including output, sealing and puncture resistance
Packaging

Pregis launches high speed bagger with predictive maintenance

The unit features an intuitive user interface and thermal printing technology, which prints bar codes, graphics and alphanumeric fonts directly onto the package
Packaging

Pregis adds bagging systems to protective packaging portfolio

The protective packaging company has acquired Sharp Packaging Systems and its flexible bagging systems capability
Packaging

Pregis acquires UK-based protective packaging company Easypack

Will expand its North American portfolio to include paper void fill, cushioning and block/brace solutions
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Embracing sustainable change through labelling choice

Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
Subscribe now